SEARCH MENU
Caspian Energy Journal Caspian European Club
Monday, 27 January 2014 09:00

Establishment of a new company to start genome information platform business

Sony Corporation ("Sony") announced that Sony, M3, Inc. ("M3") and Illumina, Inc. ("Illumina") have agreed to form a collaboration to launch a "genome information platform" in Japan. Sony and M3 will establish a new company with Illumina as a minority investor, by the end of February, 2014.

Genome research, which analyzes human genetic data alongside medical and other information, has the capacity to lead to breakthroughs in identifying the origins of diseases, as well as the development of new medicines and methods of treatment. There is growing anticipation for advances in the field of personalized medicine, where medication or treatments are optimized for the individual patient, and this is an area where genome research findings are expected to play an increasingly important role, Caspian Energy News (www.caspianenergy.net) reports with reference to the press service of Sony.

The new company's "genome information platform" business will provide a genome analysis service for research institutions and enterprises in Japan. It will also aggregate genome data with related information such as medical data to support research in areas where genome data is applied. As a result, the company will aim to contribute to advancements in Japanese personalized medicine and healthcare. Going forward, the scope of its business is expected to extend beyond medical research, to provide a service platform that supports the use of genetic data and medical information for personalized medicine and healthcare services for individual patients.

Read 631 times
POWERED BY ZEYNURBABAYEV